Literature DB >> 32081435

CLP1 acts as the main RNA kinase in mice.

Hiroyuki Fujinami1, Hiroshi Shiraishi2, Kazumasa Hada2, Masanori Inoue2, Ikuko Morisaki2, Ryoko Higa3, Toshitaka Shin4, Takashi Kobayashi3, Reiko Hanada5, Josef M Penninger6, Hiromitsu Mimata4, Toshikatsu Hanada7.   

Abstract

CLP1 plays an essential role in the protein complex involved in mRNA 3'-end formation and polyadenylation as well as in the tRNA splicing endonuclease (TSEN) complex involved in the splicing of precursor tRNAs. NOL9 localizes in the nucleolus of cells and plays an essential role in ribosomal RNA maturation. Both CLP1 and NOL9 are RNA kinases that phosphorylate the 5' end of RNAs. From the evidence that phosphorylation of the 5' end of a siRNA is essential for its efficient RNA cleavage, it was expected that CLP1 and NOL9 would be corresponding molecules. However, there had been no direct evidence that this is the case. In this study, murine NOL9 showed no apparent RNA kinase activity in cells or even in an RNA kinase assay using recombinant murine NOL9 protein. Although siRNA efficiency was decreased in CLP1 kinase-dead (Clp1K/K) cells, it was not influenced by NOL9 overexpression. These findings indicate that in mouse cells it is CLP1 that mainly acts to phosphorylate the 5' end of RNAs in the siRNA pathway, with no apparent involvement of NOL9.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLP1; NOL9; RNA kinase; siRNA

Year:  2020        PMID: 32081435     DOI: 10.1016/j.bbrc.2020.02.066

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  CLP1 is a Prognosis-Related Biomarker and Correlates With Immune Infiltrates in Rheumatoid Arthritis.

Authors:  Zhenyu Zhao; Shaojie He; Sheng Tang; Xiaofeng Lai; Jie Ren; XinCheng Yu; Jinhua Lin; Mohan Wang; Mariya M El Akkawi; Shan Zeng; Dingsheng Zha
Journal:  Front Pharmacol       Date:  2022-06-01       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.